Fuchs uveitis syndrome is an unilateral chronic recurrent non-granulomatous uveitis syndrome first described in 1906 by Fuchs, and its diagnosis is determined based on clinical manifestations. In this paper, the clinical manifestations and ocular signs of 27 patients were studied in detail. We found FUS patients were characterized by a mild uveitis with characteristic stellate KPs, iris heterochromia, iris nodule, complicated cataract and vitreous inflammatory reaction in this study. Immune mediators play a crucial role in specific viral intraocular inflammation. The incidence of complicated cataract in FUS patients is positively correlated with the AH inflammatory cytokine levels.
The clinical features of FUS have been described in many studies, including blurred vision, stellate KP, iris heterochromia, iris nodules, anterior chamber and vitreous opacities. FUS is the most easily misdiagnosed uveitis because a comprehensive understanding of it is lacking, there are hidden incidence and its pathological mechanisms are complex. In the present study, the most common symptoms were blurred vision and floaters. Stellate KPs were noted in 16 eyes (57%). Heterochromia was observed in 21% of affected eyes. Iris nodules were present in 36% of the affected eyes. These results are similar to the above-mentioned studies.
FUS is an unilateral chronic recurrent non-granulomatous uveitis syndrome accounts for 2~11% of all uveitis. In our study, we tried to detect the levels of cytokines in the AH of FUS patients and showed several cytokines were significantly increased compared to the controls. Vascular endothelial growth factor (VEGF) is produced by endothelial cells, activated T lymphocytes. It increases vascular permeability significantly and is associated with inflammatory and immune-mediated pathology. VEGF concentrations increased significantly in the plasma of Behçet disease (BD) patients and in the AH of patients with uveitis with associated cystoid macular edema (CME). Paroli et al. found VEGF levels were significantly higher in both the AH and serum of uveitis patients as compared with control subjects. Simsek et al. also suggested that VEGF levels were higher in the AH of patients with FUS than healthy controls. In the present study, we found that VEGF levels were significantly higher in FUS patients compared to controls, emphasizing the possible role of VEGF in intraocular inflammatory diseases.
In our study, we detected significantly increased levels of immune mediators in FUS patients compared with senile cataract eyes. The intraocular inflammatory factors level correlated positively with age, age may be a confounding factor affecting the levels of intraocular inflammatory factors. But in this study, although the age of cataract group is bigger than the FUS group, the intraocular inflammatory factors level in the cataract group is lower than that of FUS patients, so we feel that age has little effect on the analysis of our results.
Ocular inflammation occurs in a variety of human disease states, inflammation is thought to be initiated by eye-reactive T cells. The T helper 1 (TH1) cells secrete IFN-γ, TNF-α, IL-2, IL-8 and mediate cellular immunity, activate macrophages to kill intracellular pathogens, and play an important role in immune regulation in the induction of organ-specific autoimmune diseases and anti-infective immunity. The Th2 cells secrete cytokines including IL-4, IL-5, IL-6, IL-10, IL-13 and mainly support humoral immunity, resisting extracellular pathogens. Some inflammatory factors may play an important role in the pathogenesis of FUS.
IL-6 can stimulate the proliferation, differentiation and function of cells involved in immune responses and play an important role in anti-infective immune response. Pohlmann D et al. found that IL-2, IL-4, IL-5, IL-6, IFN-γ and TNF-α were significantly higher in FUS and Posner-Schlossman-Syndrome patients compared to controls. In another study, T. gondii patients had twofold higher levels of IL-6 as compared to healthy subjects, which seems to confirm the presence of an inflammatory state. Our study also found an increase in the level of IL-6 in FUS patients.
High IL-10 levels are mainly associated with active infectious uveitis and are considered to be important in early stages of infection. In the previous study, a significant positive correlation between VKH disease and high levels of IL-10 was found by El-Asrar et al. Sijssens et al. found that high IL-10 levels are associated with active infectious uveitis are considered to be important in early stage of infection. Joanna et al. also found the level of IL-10 to be fivefold higher in the course of toxoplasmosis than in healthy controls. In FUS patients, increased levels of IL-10 are assumed to imply a distinctively acute inflammation triggered by RV. In our study, we detected significantly increased levels of IL-10 in FUS patients compared with normal eyes.
Mo JS et al. found that IL-8 played a key role in the pathogenesis of intraocular inflammation in a rabbit model of uveitis. In the studies of humans, high levels of IL-8 have been detected in the aqueous humor of patients with acute anterior uveitis, Behçet disease (BD) or Vogt-Koyanagi-Harada (VKH) disease. Simsek et al. also emphasized IL-8 levels were significantly higher in the aqueous humor of patients with FUS than in the AH of control subjects. We also found high IL-8 levels in FUS patients. IL-8 is a cytokine secreted by TH1 cells, which mainly mediate the production of immune antibodies related to the organism’s local inflammatory reaction and participate in cellular immunity and delayed hypersensitivity inflammation. IL-8 may act as a marker for inflammation in the AH in FUS. In our study, we detected immune mediators (IL-6, IL-8 and IL-10) increased significantly in FUS patients compared with cataract eyes, suggesting that IL-6, IL-10 and IL-8 may play an important role in anti-infective immune response and contribute to the viral response in FUS.
Cataract is a common complication of chronic or recurrent uveitis and is a sequelae to chronic intraocular inflammation and topical corticosteroid therapy. Cataracts occur in many types of uveitis, such as juvenile idiopathic arthritis-associated uveitis, BD, VKH and ocular toxoplasmosis. Cataract occurs in 17%–36% of ocular BD patients and the most frequent complication is cataract. In VKH, cataract is the most common complication, with a prevalence of about 40%. The expression of pro-inflammatory cytokines in the cataract formation of non-infectious uveitis is gradually understood. Recurrent uveitis attacks may lead to lens permeability, then result in cataract. Previous studies have emphasized that cataract is the most common complications in FUS patients. Tugal-Tutkun et al. found a 56% risk of cataract formation in FUS patients over their 8-year follow-up period. Yang et al. found cataract was appeared in 70.7% of their FUS patients. Similarly, cataract was observed in 57.14% of patients in our study. The use of hormonal drugs to treat of inflammation also promotes the development of cataract.
Our research speculated that the occurrence of complicated cataract in FUS patients may be closely related to intraocular inflammation. Previous studies have confirmed that there is a correlation between inflammatory factors in the AH of uveitis patients and the occurrence of cataract. Tumor necrosis factor-α (TNF-α) can increase the mRNA level of laminin and type IV collagen, cause lens capsule fibrosis and the proliferation and migration of lens epithelial cells (LEC), thereby promoting the development of cataract. Transforming growth factor-β (TGF-β), which can induce lens cell pathology and lead to fibrotic cataract formation. Recently, few studies have explored the association between cataract in FUS patients and the high expression of inflammatory cytokines in the AH. Thus, the relationship between the levels of intraocular cytokines and cataract in FUS is evaluated in this study.
Previous studies have confirmed that IL-1 can promote the proliferation of LEC and collagen synthesis, then resulting in the formation of cataract. There are also some researches revealed that IL-1β can promote the expression of IL-6 and IL-8 through different pathways. Hu et al. first reported the expression and secretion of IL-6 by human uveal melanocytes (UMs) and found IL-1β increases expression and secretion of IL-6 via the p38 MAPK/NF-kappaB pathway. Liu et al. revealed that IL-1β induces IL-6 production in Müller cells by activation of IL-6 promoter activity predominantly through the p38 MAPK/NF-κB pathway. IL-1β potently stimulates IL-8 expression in Müller cells mainly through the p38 MAPK and ERK1/2 pathways. Chang et al. also found the important role of IL-1β in pulpal inflammatory responses via stimulation of IL-8 and ICAM-1 expression and secretion. The triggering effects of the inflammatory mediators, such as IL-1 and IL-6, may have an early stimulating effect on posterior capsular opacification (PCO) formation, and the actions of IL-1 may be mediated through the production of IL-6. In this study, there was a statistically significant positive correlation between the severity of cataract in FUS patients and IL-6 and IL-8 levels. These results confirmed that the occurrence of complicated cataract in FUS patients is positively correlated with the high expression of inflammatory factors. Further studies are needed to confirm their exact effect on the course of uveitis and complicated cataract.
The study has also several limitations. Firstly, this study only analyzed some inflammatory factors (IL-6, IL-10 and IL-8) in the AH of FUS patients, but did not explore the progression of other inflammatory factors in the AH, such as IL-1, TNF-α and TGF-β during the course of FUS, and their associations with cataract formation. Secondly, the sample size of this study was relatively small, which may have limited the statistical strength of the analysis.